NEVADA ONCOLOGY SOCIETYPub 78
Pub 78
Balance Sheet
Fiscal Year: 2025
Assets in 2025 (Year End)
$617,381
Cash & Equivalents
50%
Investments
43%
Receivables (Non-Related)
4%
Prepaid Expenses
3%
Related-Party Receivables
0%
Inventories
0%
Property, Plant, & Equipment (net)
0%
Other Assets
0%
Liabilities in 2025 (Year End)
$102,692
Payables & Accruals
97%
Deferred Revenue
3%
Grants Payable
0%
Tax-Exempt Bond Liabilities
0%
Custodial & Escrow Liabilities
0%
Notes Payable / Debt (Non-Related)
0%
Related-Party Payables
0%
Other Liabilities
0%
Assets
2024
2025
Change
Cash & Equivalents
$554,551
$306,810
-45%
Receivables (Non-Related)
-
$26,000
-
Related-Party Receivables
-
-
-
Inventories
-
-
-
Prepaid Expenses
$17,722
$20,981
+18%
Investments
$54,938
$263,590
+380%
Property, Plant, & Equipment (net)
-
-
-
Other Assets
-
-
-
Total Assets
$627,211
$617,381
-2%
Liabilities
2024
2025
Change
Payables & Accruals
$65,415
$99,692
+52%
Grants Payable
-
-
-
Deferred Revenue
-
$3,000
-
Tax-Exempt Bond Liabilities
-
-
-
Custodial & Escrow Liabilities
-
-
-
Notes Payable / Debt (Non-Related)
-
-
-
Related-Party Payables
-
-
-
Other Liabilities
-
-
-
Total Liabilities
$65,415
$102,692
+57%
Net assets
2024
2025
Change
Restricted Net Assets
-
-
-
Unrestricted Net Assets
$561,796
$514,689
-8%
Net assets
2024
2025
Change
Net assets
+$561,796
+$514,689
-8%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)